ArticleEuropean radiology2026
Thermal ablation for radioactive iodine refractory cervical lymph node metastasis in differentiated thyroid cancer.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTherapeutic management of radioactive iodine-refractory lymph node metastasis (RAIR-LNM) in differentiated thyroid cancer remains challenging. Thermal ablation for RAIR-LNM has gained a paucity of evidence for clinical guidelines. MATERIALS AND
methodsThis multicenter retrospective study analyzed 88 patients with 182 RAIR-LNM at 5 Chinese hospitals between June 2011 and July 2022, to evaluate the effectiveness of thermal ablation for RAIR-LNM. All included patients had at least one ≤ 3 cm RAIR-LNM. The main outcomes were the technical success and disease progression rate. Secondary outcomes included volume reduction rate (VRR), tumor disappearance ratio and the complication rate. Subgroup analyses were performed by using Kaplan-Meier curves and Cox proportional hazards regression models.
resultsThe mean diameter was 1.35 ± 0.65 cm. The technical success rate was 100% and all elevated thyroglobulin (Tg) levels returned to normal after ablation. Over a mean follow-up period of 55.3 ± 31.39 months, disease progression occurred in 18.18% of patients (16 of 88). Subgroup analysis revealed significantly reduced rates of disease progression (p < 0.05) and new LNM development in patients with Tg ≤ 35 μg/L. Multivariable analysis identified Tg level as a predictor associated with new LNM and disease progression, whereas tumor size and ablation modality showed no statistically significant associations. LNM shrank evidently after ablation, and the disappearance rate was higher for LNM ≤ 1 cm. The overall complication rate was 10.23% (9 of 88).
conclusionsThermal ablation emerges as a viable therapeutic strategy for RAIR-LNM, offering durable local tumor control and prolonged progression-free survival, especially for patients with Tg < 35 μg/L. KEY POINTS: Question Whether thermal ablation for radioactive iodine refractory lymph node metastasis could achieve a long-term survival benefit. Findings Reduced rates of disease progression and new lymph node metastasis development were found in patients with thyroglobulin ≤ 35 μg/L. Clinical relevance Thermal ablation serves as a viable therapeutic strategy for patients with radioactive iodine-refractory lymph node metastasis. It offers durable local tumor control and prolonged progression-free survival, especially for patients with lower thyroglobulin levels.
Indexed as
Identifiers
40684066What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.